A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

Conclusion For Chinese patients with pre-treated advanced solid malignancies, 4  mg/kg of aflibercept in combination with FOLFIRI was well-tolerated, demonstrated preliminary anti-tumor activity and had a PK profile consistent with that in Caucasian patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research